On Tuesday, Stifel financial analysts adjusted their outlook for Johnson & Johnson (NYSE:JNJ) shares, raising the price target to $170 from the previous $160 while maintaining a Hold rating on the stock. The revision follows Johnson & Johnson's third-quarter performance, which surpassed both Stifel's and the consensus estimates, particularly due to the pharmaceutical division's stronger-than-expected results.
Johnson & Johnson's third-quarter sales and earnings per share (EPS) exceeded expectations, a factor that contributed to the analyst's updated price target. The company's initial commentary for the year 2025 indicates that its business fundamentals are expected to remain consistent. CFO Joe Wolk provided a positive outlook on several aspects of the company's growth strategy for 2025, including anticipated sales exceeding $57 billion in the Innovative Medicine (Pharma) sector. This growth is anticipated despite the expected decline in STELARA's exclusivity.
Wolk also highlighted the potential for growth in the 2025 MedTech sector, which is projected to be at the upper end of the 5%-7% long-term range. This optimism is partly due to the launch of the Varipulse PFA catheter, contributions from high-growth acquisitions, and technologies that could accelerate orthopedic growth. Furthermore, Wolk suggested that the current consensus on the company's operating margins for 2025, which is around 32.5%, seems plausible.
In summary, the analysts left the recent company call with a more positive view that their projections, as well as the consensus for 2025, accurately reflect Johnson & Johnson's outlook. Despite this positive sentiment, the analysts believe that the company's current stock valuation is fair, which underpins their decision to maintain a Hold rating with a revised price target of $170.
InvestingPro Insights
Johnson & Johnson's strong financial position and market standing are further underscored by recent data from InvestingPro. The company's P/E ratio of 20.75 over the last twelve months as of Q2 2024, coupled with a PEG ratio of 0.11, suggests that the stock may be undervalued relative to its earnings growth potential. This aligns with the Stifel analysts' decision to raise the price target, reflecting potential upside.
An InvestingPro Tip highlights that J&J has raised its dividend for 53 consecutive years, demonstrating a strong commitment to shareholder returns. This is particularly relevant given the company's robust financial outlook for 2025, as discussed in the article. Additionally, J&J's revenue growth of 5.13% over the last twelve months supports the positive commentary on the company's growth strategy.
Another InvestingPro Tip notes that J&J is trading near its 52-week high, which corroborates the analysts' view of fair valuation. For investors seeking more comprehensive analysis, InvestingPro offers 11 additional tips for Johnson & Johnson, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.